Related Experiment Video

Updated: Jul 21, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K

Nrf2: a dark horse in doxorubicin-induced cardiotoxicity

Xiaopeng Zhao1, Zheng Tian1, Mingli Sun2

  • 1College of Exercise and Health, Shenyang Sport University, Shenyang, Liaoning, 110102, China.

Cell Death Discovery
|July 26, 2023
PubMed

Insights

Doxorubicin is a vital anticancer drug, but its cardiotoxicity is a major issue. This study explores how targeting Nrf2 (Nuclear factor erythroid 2-related factor 2) can help prevent this doxorubicin-induced cardiotoxicity.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiology

Background:

  • Doxorubicin is a crucial broad-spectrum anticancer agent.
  • Doxorubicin-induced cardiotoxicity presents a significant clinical challenge.
  • Oxidative stress, cell death, and inflammation are key pathological mechanisms involved.

Purpose of the Study:

  • To introduce the role of Nrf2 (Nuclear factor erythroid 2-related factor 2) in doxorubicin-induced cardiotoxicity.
  • To discuss the pathological mechanisms of doxorubicin-induced cardiotoxicity.
  • To summarize therapeutic strategies targeting Nrf2.

Main Methods:

  • Literature review on Nrf2's role in oxidative stress, cell death, and inflammation.
  • Analysis of studies investigating Nrf2 activation for preventing doxorubicin-induced cardiotoxicity.
  • Synthesis of information on therapeutic modalities targeting Nrf2.

Main Results:

  • Nrf2 plays a critical role in cellular defense against oxidative stress.
  • Nrf2 is implicated in the pathological pathways of doxorubicin-induced cardiotoxicity.
  • Activating Nrf2 has shown promise in ameliorating doxorubicin-induced cardiotoxicity.

Conclusions:

  • Nrf2 is a key mediator in the cellular response to doxorubicin.
  • Targeting Nrf2 represents a promising therapeutic avenue to mitigate doxorubicin-induced cardiotoxicity.
  • Further research into Nrf2-activating therapies is warranted for clinical application.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.6K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
17
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16